患有多发性硬化症的人群的神经结果,接受了针对瘤征兆的免疫检查点抑制剂治疗

Carson M Quinn1, Prashanth Rajarajan1, Alexander J Gill1

  • 1From the Department of Neurology (C.M.Q., P.R., S.E.C., S.B.), Brigham and Women's Hospital, Boston, MA; Department of Neurology (A.J.G., J.C.P.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Neurology (H.K., T.E.B., I.K.), NYU Grossman School of Medicine, New York; Department of Neurology (A.B.W., E.A.), University of Colorado School of Medicine, Aurora; Department of Neurology (C.S.d.C., V.B.), Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ; Department of Neurology (J.L., P.C.), Stony Brook University Medical Center, NY; Sidney Kimmel Comprehensive Cancer Center (J.C.M.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Neurology (K.M.G.), Stanford University, CA; Medical Partnership 4 MS+ (MP4MS+) (D.K.), LaBelle, FL.

Neurology
|November 14, 2024
PubMed
概括

免疫检查点抑制剂 (ICI) 很少在患有多发性硬化症的老年癌症患者中引起新的多发性硬化症 (MS) 活性或神经系统副作用. 这些发现表明ICI可能对老年多发性硬化患者安全,但对年轻人需要更多的研究.